JPMorgan Chase Raises Voting Rights in Evotec to 6.54%
JPMorgan Chase increased its total voting rights in Evotec to 6.54% from 5.64%.
Related stories
Alnylam Reports Quarterly Results Through September 30
Alnylam Pharmaceuticals reported results for the quarter ended September 30. The alert provides no financial figures.
M impact | EQUITY | Oct 29, 2026, 07:15 PM UTC
Riverview Bancorp Reports $2.0 Million Second-Quarter Profit
Riverview Bancorp reported net income of $2.0 million, or $0.10 per diluted share, for the fiscal second quarter ended September 30, 2026. Net interest income was $11.8 million and
M impact | EQUITY | Oct 29, 2026, 07:13 PM UTC
Ligand Pharmaceuticals Reports Quarterly Results Through September 30
M impact | EQUITY | Oct 29, 2026, 07:13 PM UTC
Allegro Microsystems Reports Quarterly Results Through September 30
M impact | EQUITY | Oct 29, 2026, 07:12 PM UTC
Group 1 Automotive Reports Third-Quarter Revenue of $5.4B
Third-quarter revenue fell 6.7% year over year to $5.4 billion. Net income rose to $102.9 million from $13 million; diluted EPS was $8.59.
M impact | EQUITY | Oct 29, 2026, 07:11 PM UTC
Visa Publishes Q4 and Full-Year 2026 Earnings Call Transcript
M impact | EQUITY | Oct 29, 2026, 07:11 PM UTC